Chris Pasquale: Thanks. Just a quick one. First, was hoping you could give us an update on the Rosa installed base exiting ’22.
Ivan Tornos: Yes, I’ll keep it short and sweet here. In any year, we expect to do no less than 300 installations, and we exceeded that expectation across all three regions. As you think about the future, ’23, ’24 and whatnot, that’s frankly the point of entry. I would be disappointed, maybe even jobless if we didn’t exceed that number, given the new applications in shoulder, next generation hip, and other technologies coming in, but we’re so far exceeding those expectations.
Chris Pasquale: Okay, and then Bryan, I thought your comment that you had not started to work through the COVID backlog yet was interesting. It certainly felt like the market had some pent-up demand benefit last year, but I understand your point that the comps weren’t exactly normal. My question is if you haven’t started to make progress on the backlog yet, do you think you ever will, and are you assuming any progress on that front in 2023?
Bryan Hanson: That is the question that I think we’re all grappling with. There’s clearly backlog. You might call it longer waiting lists, backlog – you can define it the way you want, but the fact is there’s pent-up demand for these procedures. The rate limiting factor is really capacity at the provider level. You could–because even it’s a supply challenged environment, maybe even capacity constraints the company level, but I think the bigger capacity constraint at this point is at the provider level. We actually had a third party run this analysis for us because we really wanted to get in tune to what is the size of the backlog based on the third party’s view, and then also when they believe the backlog would start coming through and at what pace.
What we found in that is that, number one, they came back with there is a very sizeable backlog in orthopedics – actually, their analysis came back smaller than what we expected, but still very material. They said that when we start to work through it, it would be constrained again because of the capacity, and it was a relatively minor impact, a tailwind for sure but impact to the overall market growth, just given the capacity constraints you’re going to have in the provider for some period of time. The good news about that, I guess, is when we start to digest the backlog, it will come as a positive tailwind, likely for years. It wouldn’t be overly material in any given year, but it would be a tailwind for multiple years, so that’s the analysis that we have and we just–again, just doing the math, we don’t believe that we’re into that backlog yet.
Hopefully we’ll see some of that come in 2023, but we’re not depending on that when you look at the center of our guidance range.
Keri Mattox: All right, Katie, I think we have time for just one final question.
Operator: We’ll take our next question from Rick Wise with Stifel.
Rick Wise: Can you hear me now? Sorry about that.
Bryan Hanson: Yes.
